CCMW
CLVS

Cypress Capital Management (Wyoming)’s Clovis Oncology, Inc. CLVS Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200
Closed – – 185
2022
Q2 		$0 Sell
200
-1,800
-90% -$2.65K ﹤0.01% 206
2022
Q1 		$4K Hold
2,000
– – ﹤0.01% 152
2021
Q4 		$5K Hold
2,000
– – ﹤0.01% 228
2021
Q3 		$9K Hold
2,000
– – 0.01% 186
2021
Q2 		$12K Hold
2,000
– – 0.01% 211
2021
Q1 		$14K Hold
2,000
– – 0.01% 184
2020
Q4 		$10K Hold
2,000
– – 0.01% 180
2020
Q3 		$11K Hold
2,000
– – 0.01% 157
2020
Q2 		$14K Hold
2,000
– – 0.01% 147
2020
Q1 		$13K Hold
2,000
– – 0.02% 123
2019
Q4 		$21K Buy
2,000
+1,150
+135% +$8.36K 0.02% 125
2019
Q3 		$3K Hold
850
– – ﹤0.01% 179
2019
Q2 		$13K Hold
850
– – 0.02% 179
2019
Q1 		$21K Hold
850
– – 0.03% 152
2018
Q4 		$15K Hold
850
– – 0.03% 198
2018
Q3 		$25K Sell
850
-650
-43% -$25.2K 0.03% 206
2018
Q2 		$68K Hold
1,500
– – 0.07% 146
2018
Q1 		$79K Sell
1,500
-300
-17% -$17.5K 0.09% 126
2017
Q4 		$122K Sell
1,800
-250
-12% -$17.5K 0.14% 110
2017
Q3 		$169K Buy
2,050
+1,500
+273% +$119K 0.2% 82
2017
Q2 		$51.5K Hold
550
– – 0.06% 119
2017
Q1 		$35K Sell
550
-450
-45% -$27.4K 0.04% 146
2016
Q4 		$41.9K Hold
1,000
– – 0.04% 138
2016
Q3 		$36K Buy
1,000
+150
+18% +$3.22K 0.05% 127
2016
Q2 		$11.7K Sell
850
-150
-15% -$2.19K 0.02% 168
2016
Q1 		$19.2K Sell
1,000
-21,910
-96% -$464K 0.03% 149
2015
Q4 		$802K Buy
22,910
+3,210
+16% +$207K 1.01% 25
2015
Q3 		$1.81M Buy
19,700
+7,400
+60% +$640K 2.33% 11
2015
Q2 		$1.08M Buy
12,300
+10,525
+593% +$901K 1.22% 25
2015
Q1 		$132K Hold
1,775
– – 0.16% 82
2014
Q4 		$99.4K Buy
+1,775
New +$93.3K 0.13% 88

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s CLVS Position: Q3 2022 in Review

Cypress Capital Management (Wyoming) sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 200 shares.

Cypress Capital Management (Wyoming) first reported a position in CLVS in Q4 2014 and held it in 31 quarters. The position peaked at $1.81M in Q3 2015. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

  • Cypress Capital Management (Wyoming) reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
  • Cypress Capital Management (Wyoming) sold 200 Clovis Oncology, Inc. shares in Q3 2022.
  • Cypress Capital Management (Wyoming) first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 31 quarters.
  • Cypress Capital Management (Wyoming)'s Clovis Oncology, Inc. position peaked at $1.81M in Q3 2015.
  • 103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q3 2022, filed 14 Nov 2022.